

December 12, 2024

## PROGRAMME OVERVIEW

update November 13, 2024

### 07:45 Registration desk open Investors Forum

For participants at the Investors Forum breakfast session. The Investors Forum is taking place at the Penthouse of CORPUS

### 08:00 Investors forum part 1 - breakfast session -

Hosted by 

MODERATOR: Dr. ir. Lisanne Blauw, Associate at Thuja Capital (NL)

*The investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, medtech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to Venture Capitalists, corporate- and regional investment funds and to discuss your business strategy.*

### 08:30 Registration desk, exhibition open

### 09:15-10:50 Plenary morning programme

Hosted by   
The future of health

### 09:15 Welcome by moderator Suzanne Spliethoff MSc.

Suzanne is a Dutch daytime speaker, presenter and actress. She completed her studies in Biomedical Sciences in 2007 and has since been a much sought-after chairperson for universities, hospitals and healthcare institutions, among others.

### 09:20 Opening by Esther Peters, Director Leiden Bio Science Park

09:30

**Keynote: The power of mRNA: transforming healthcare beyond COVID-19**  
by Jolanda Crombach, Managing Director at Moderna

In this presentation, Jolanda Crombach, Managing Director of Moderna Netherlands, will discuss how Moderna has evolved from over 12 years of R&D and the success of its COVID-19 mRNA vaccine into a multi-product company at the forefront of innovation. The foundation of Moderna is built on a key principle: if mRNA works as a medicine for one disease, it has the potential to work for many others. Jolanda will explain how mRNA technology —by instructing the body to create its own medicines— has the potential to address not only infectious diseases like COVID-19 and RSV but also cancer, rare diseases, and autoimmune disorders. Jolanda will provide a comprehensive overview of mRNA technology and its production process, illustrating how its rapid and flexible development capabilities are revolutionizing healthcare. She will also explain the pivotal role AI plays in driving innovation and efficiency across Moderna's R&D and wider operations. Additionally, Jolanda will touch on incorporating new technologies into the Dutch healthcare system. Finally, she will showcase how Moderna's pipeline and strategic collaborations, including the mRNA Access program, are shaping the future of healthcare and amplifying the impact of mRNA technology.

Followed by a panel discussion with

- Jolanda Crombach, Managing Director at Moderna
- Annemiek Verkamman, Managing Director at hollandbio
- Sahar van Waalwijk van Doorn-Khosrovani, Pharmacist / Associate Professor, Member of National Funder's Committee for Evaluation of Specialised Medicine & MDx at CZ, LUMC

10:20

**Venture Challenge**

Hosted by

**Health~Holland**

*The winner of the Venture Challenge Fall 2024 will be announced!*



Presentation by **Dr.ir. Chrétien Herben**, Program Director Life Sciences@Work

10:40

**Break**

Time for networking and to visit the exhibition

**11:30-12:45 Parallel morning sessions**




<p><b>Impact Investing: How it helps the value proposition of entrepreneurs</b></p> <p><i>Hosted by</i></p>  <p>Moderator: <b>Carine van den Brink</b></p>	<p>Life sciences in Europe is experiencing a transformative shift by impact investing. This evolving trend underscores the prioritisation of investments that deliver measurable social and environmental benefits alongside financial returns. This session will inform you about the evolving trends of impact investing in life sciences, and to show startups how they could benefit from clearly defined impact goals to attract funding and become successful.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Eleanor Price PhD</b>, Associate at Thuja Capital</li> <li>▪ <b>Dr. Stephanie Mooij</b>, Head of Responsible Investment at Gilde Healthcare</li> <li>▪ <b>Dr. Rachel Abbott</b>, Chief Executive Officer at Pan Cancer T</li> </ul>
<p><b>Should you stay independent as a medical device company, or not?</b></p> <p><i>Hosted by</i></p>  <p>Moderator: <b>Raimon Keijzer</b></p>	<p>Medical technology companies create life changing innovations allowing people to live longer and healthier. In the rapidly evolving medical device industry, entrepreneurs face critical decisions that can shape the future of their companies. This session will explore the strategic considerations behind remaining independent versus pursuing a M&amp;A or IPO. We will delve into key factors such as financing options, growth strategies, and the lessons learned from industry leaders who have navigated these crossroads. Join us to gain insights into the benefits and challenges of independence, and how to make informed decisions that align with your long-term vision.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Luc Segers</b>, Division Head, Business &amp; Communications at QbD</li> <li>▪ <b>Prof. Dr. Wiro Niessen</b>, Dean Faculty Medical Sciences, University of Groningen; Board Member UMCG / Founder Quantib</li> <li>▪ <b>Bram Schermers</b>, CEO/CTO Sirius Medical Systems</li> </ul>
<p><b>Cell therapy: The investment landscape and clinical insights</b></p> <p><i>Hosted by</i></p>  <p>Moderator: <b>Dr. Thilo Buck</b></p>	<p>The Global Cell Therapy Market is witnessing unprecedented growth and innovation, revolutionizing the landscape of medical treatment. In this session we will dive into the trends and developments in this area including innovations, application fields, entrepreneurial strategies and investment landscape. Also the challenges in clinical trials will be discussed.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Dr. Frank van Engelenburg</b>, Managing Consultant at Progress – Experts in Life Sciences</li> <li>▪ <b>Chantal van Litsenburg</b>, Manager - translational effectiveness LUMC</li> <li>▪ <b>Dr. Jan De Kerpel</b>, Managing Director - Head Life Sciences &amp; Healthcare at Van Lanschot Kempen Investment Banking</li> </ul>

**12:45-14:00 Lunch**

Time for networking and to visit the exhibition

**13:00 Investors forum part 2 - lunch session –**

14:00-15:15 Parallel afternoon sessions

<p><b>Strategies to extend runway and lowering costs in life sciences</b></p> <p>Hosted by </p> <p>Moderator:</p>	<p>In the current environment where young companies seeking to secure or extend their funding rounds, inflation is increasing input costs, and regulatory authorities continue to emphasize cost controls to maintain the affordability of medicines and treatments, finding ways to reduce costs while maintaining quality and speed to market becomes competitive advantage. Through expert-led presentations and discussions participants will learn to identify and implement effective cost-saving measures and funding extension strategies. This session aims to empower participants with the knowledge to sustain growth and innovation amidst financial challenges.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Peter Jones</b>, Principal Business Consultant at QAD</li> <li>▪ <b>Dr. Hans Preusting</b>, CEO Synerkine Pharma</li> <li>▪ <b>Ronald van der Geest PhD</b>, Managing Partner 3D-PharmXchange</li> </ul>
<p><b>Meeting the sustainability challenge in life sciences</b></p> <p>Hosted by </p> <p>Moderator: <b>Martijn Kramer MSc.</b></p>	<p>The entire life sciences process, from R&amp;D to end-of-line product, including medical devices, vaccines and pharmaceuticals, demands substantial resources. While other manufacturing sectors might freely experiment with sustainable alternatives and efficiency improvements, life sciences must navigate the additional hurdles of validation and regulatory compliance with each modification to their processes. In this session experts will discuss how to implement sustainability in Life sciences? What are the best practices and what hasn't worked. Furthermore, the role of partnerships in the value chain in promoting sustainability will be addressed.</p>	<p>Presentations by and panel discussion with:</p> <ul style="list-style-type: none"> <li>▪ <b>Samuel Aleman</b>, Sr. Director Commercial Strategy EMEA - Clean Energy &amp; Sustainability at Thermo Fisher Scientific</li> <li>▪ <b>Prof. dr. Schelto Kruijff</b>, Professor of sustainable surgical oncology UMCG/University of Groningen</li> <li>▪ <b>Bram de Moor</b>, Project Leader Urimon study</li> </ul>
<p><b>The road to IPO</b></p> <p>Hosted by </p> <p>Moderator:</p>	<p>In line with the broader IPO market, activity in the pharmaceutical, biotech, and medtech industry has been subdued over the last few years. While there has been a recent uptick in activity driven by advancements in technology and decreasing interest rates, the IPO process remains challenging. To attract investors, life science leaders must not only deliver a clear equity story, but also ensure their organisation is public-company ready with a robust regulatory, corporate, and environmental governance framework. This session will be led by PwC IPO experts who will be joined by a panel of life sciences executives who recently navigated the IPO journey.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Lena Takehana</b>, Director at PwC - Capital Markets &amp; Accounting Advisory</li> <li>▪ <b>Louise Kooij</b>, Chief Accounting Officer at NewAmsterdam Pharma</li> <li>▪ To be announced</li> </ul>

15:15 **Break** - Time for networking and to visit the exhibition

16:00 **Wrap up conference**

16:05 **Announcement and pitch winner Investors Forum**

16:20 **Keynote: A refreshing look at technology, innovation, and our future**  
by **Deborah Nas**, Speaker | Author | Innovator

Digital technologies are changing industries faster than ever, but not everyone is on board. People, company processes, and regulations often slow down innovation. In her keynote, Deborah will dive into why some resist new technologies and why startups are so important in pushing progress forward. She'll also share examples of how AI and quantum technologies are set to spark the next big breakthroughs in life sciences.

Deborah captivates every audience with her inspiring presentations filled with easy-to-understand yet surprising examples. By placing technological developments in both a societal and business context, she illustrates what is already happening today and what we can expect in the future. Deborah is renowned for her bespoke presentations.

She is a technology enthusiast, professor, keynote speaker and active participant in the tech innovation space. Being an entrepreneur, consultant and non-executive board member, she knows what it takes to make innovation happen.

---

17:00 **Reception** - Time for networking and to visit the exhibition  
*Hosted by*




---

18:30 **End of the Dutch Life Sciences conference**

*Note: the organisation keeps the right to make changes to the programme at any time.*